RT Journal Article SR Electronic T1 Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.30.21261234 DO 10.1101/2021.07.30.21261234 A1 Ryan, Feargal J. A1 Hope, Christopher M. A1 Masavuli, Makutiro G. A1 Lynn, Miriam A. A1 Mekonnen, Zelalem A. A1 Lip Yeow, Arthur Eng A1 Garcia-Valtanen, Pablo A1 Al-Delfi, Zahraa A1 Gummow, Jason A1 Ferguson, Catherine A1 O’Connor, Stephanie A1 Reddi, Benjamin AJ A1 Shaw, David A1 Kok-Lim, Chuan A1 Gleadle, Jonathan M. A1 Beard, Michael R. A1 Barry, Simon C. A1 Grubor-Bauk, Branka A1 Lynn, David J. YR 2021 UL http://medrxiv.org/content/early/2021/08/03/2021.07.30.21261234.abstract AB Increasing evidence suggests immune dysregulation in individuals recovering from SARS- CoV-2 infection. We have undertaken an integrated analysis of immune responses at a transcriptional, cellular, and serological level at 12, 16, and 24 weeks post-infection (wpi) in 69 individuals recovering from mild, moderate, severe, or critical COVID-19. Anti-Spike and anti-RBD IgG responses were largely stable up to 24wpi and correlated with disease severity. Deep immunophenotyping revealed significant differences in multiple innate (NK cells, LD neutrophils, CXCR3+ monocytes) and adaptive immune populations (T helper, T follicular helper and regulatory T cells) in COVID-19 convalescents compared to healthy controls, which were most strongly evident at 12 and 16wpi. RNA sequencing suggested ongoing immune and metabolic dysregulation in convalescents months after infection. Variation in the rate of recovery from infection at a cellular and transcriptional level may explain the persistence of symptoms associated with long COVID in some individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by grants from The Hospital Research Foundation, Flinders Foundation, The Womens and Childrens Hospital Foundation, and the Flinders University College of Medicine and Public Health COVID-19 grant scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study participants were recruited via the Central Adelaide Health Network (CALHN). The study was performed in accordance with the ethical principles consistent with the latest version of the Declaration of Helsinki (version Fortaleza 2013), Good Clinical Practice (GCP) and according to the National Health and Medical Research Council (NHMRC) Guidelines for Research published in the National Statement on the Ethical Conduct in Human Research (2007; updated 2018). The protocol was approved CALHN Human Research Ethics Committee, Adelaide, Australia (Approval No. 13050)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA-Seq data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE169687. Count tables, metadata, and R code for all analyses (serology, flow cytometry and RNA-Seq) have been uploaded to the Lynn Laboratory BitBucket (https://bitbucket.org/lynnlab/covid-sa).